Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals's GHG Emissions Data Preview
In 2023, Ionis Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).
However, Ionis Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Ionis Pharmaceuticals's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of Ionis Pharmaceuticals amounted to 5,483 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Ionis Pharmaceuticals increased by 27.6%, suggesting that the company faced challenges in reducing its emissions from its core operations.
Ionis Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Ionis Pharmaceuticals's Scope 1 emissions?
In 2023, the total Scope 1 emissions of Ionis Pharmaceuticals were 2,695 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Ionis Pharmaceuticals reduced its Scope 1 emissions over time?
Since 2021, Ionis Pharmaceuticals's Scope 1 emissions have increased by 5.03%, reflecting a rising long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), Ionis Pharmaceuticals's Scope 1 emissions increased by 9.73%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.
What are Ionis Pharmaceuticals's Scope 2 emissions?
In 2023, Ionis Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 2,788 tCOâ‚‚e using the market-based method.
Has Ionis Pharmaceuticals reduced its Scope 2 emissions over time?
Since 2021, Ionis Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Market-Based) have increased by 35.87%, reflecting a rising long-term trend in Scope 2 emissions over time.
Compared to the previous year (2022), Ionis Pharmaceuticals's Scope 2 emissions (Market-Based) rose by 51.44% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy
What methodology does Ionis Pharmaceuticals use for Scope 2 reporting?
In 2023, Ionis Pharmaceuticals reported its Scope 2 emissions using the market-based method.
Ionis Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 Market-Based